Darbepoetin alfa ‘similar biologic’ launched in India

Biosimilars/News | Posted 20/06/2014 post-comment0 Post your comment

India-based Hetero, one of the largest manufacturers and suppliers of active pharmaceutical ingredients (APIs) to the Indian pharmaceutical industry, announced on 18 June 2014 the launch of its first ‘similar biologic’ product Actorise, a ‘similar biologic’ of darbepoetin alfa in India.

India V13C03

Darbepoetin alfa is a synthetic form of erythropoietin, which stimulates erythropoiesis (increases red blood cell levels) in patients with anaemia due to chronic kidney disease or cancer chemotherapy. More than 100,000 new patients in India every year need renal replacement therapy, i.e. dialysis, and chronic kidney disease is a rapidly growing issue in India. Drugs such as darbepoetin alfa are therefore essential to maintain haemoglobin levels and reduce the need for blood transfusions.

The ‘similar biologic’ will be marketed in collaboration with Indian generics maker Cipla. This will be Cipla’s second ‘similar biologic’. The company launched its first ‘similar biologic’ Etacept (etanercept), which is a version of Amgen’s arthritis blockbuster Enbrel (etanercept), in India in April 2013 [1].

Actorise is a ‘similar biologic’ of Amgen’s blockbuster anaemia treatment Aranesp (darbepoetin alfa). The patents on Aranesp are set to expire in Europe in July 2016 and in the US in May 2024 [2].

Editor’s comment
It should be noted that ‘similar biologics’ approved in India might not have been authorized following as strict a regulatory process as is required for approval of biosimilars in the EU. The EMA (European Medicines Agency) regulatory requirements ensure the same high standards of quality, safety and efficacy for biosimilars as for originator biologicals, and also include a rigorous comparability exercise with the reference product.

Related article

‘Similar biologics’ approved and marketed in India

1. GaBI Online - Generics and Biosimilars Initiative. Cipla launches first etanercept ‘similar biologic’ in India [www.gabionline.net]. Mol, Belgium: Pro Pharma Communications International; [cited 2014 Jun 20]. Available from: www.gabionline.net/Biosimilars/News/Cipla-launches-first-etanercept-similar-biologic-in-India
2. GaBI Online - Generics and Biosimilars Initiative. US$67 billion worth of biosimilar patents expiring before 2020 [www.gabionline.net]. Mol, Belgium: Pro Pharma Communications International; [cited 2014 Jun 20]. Available from: www.gabionline.net/Biosimilars/General/US-67-billion-worth-of-biosimilar-patents-expiring-before-2020

Permission granted to reproduce for personal and non-commercial use only. All other reproduction, copy or reprinting of all or part of any ‘Content’ found on this website is strictly prohibited without the prior consent of the publisher. Contact the publisher to obtain permission before redistributing.

Copyright – Unless otherwise stated all contents of this website are © 2012 Pro Pharma Communications International. All Rights Reserved.

Source: The Hindu

comment icon Comments (0)
Post your comment
Related content
Most viewed articles
About GaBI
Home/About GaBI Posted 06/08/2009
EU guidelines for biosimilars
EMA logo 1 V13C15
Home/Guidelines Posted 08/10/2010